2-amino-N-(4-benzamidophenyl)-4-hydroxy-5-methoxybenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-N-(4-benzamidophenyl)-4-hydroxy-5-methoxybenzamide
• 化学式: C₂₁H₁₉N₃O₄
• 分子量: 377.4
• InChiKey: CKGRPOQFYXSXGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  114
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 20% palladium hydroxide-activated charcoal 、 氢气 作用下， 35.0~50.0 ℃ 、101.33 kPa 条件下， 生成 2-amino-N-(4-benzamidophenyl)-4-hydroxy-5-methoxybenzamide
  参考文献：
  名称：

  Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping

  摘要：

  An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J. 2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases. Virtual screening identified fragments that could be fused into the core scaffold, exploiting additional binding interactions and thus improving potency. These efforts resulted in a hybrid compound with target potency increased by a 1000-fold, while maintaining selectivity against selected protein kinases and an improved level of solubility and protein binding. Despite these significant improvements no significant antibacterial activity was yet observed within this class. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.08.017

文献信息

• Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping
  作者：Peter Doig、P. Ann Boriack-Sjodin、Jacques Dumas、Jun Hu、Kenji Itoh、Kenneth Johnson、Steven Kazmirski、Tomohiko Kinoshita、Satoru Kuroda、Tomo-o Sato、Kaori Sugimoto、Katsumi Tohyama、Hiroshi Aoi、Kazusa Wakamatsu、Hongming Wang

  DOI：10.1016/j.bmc.2014.08.017

  日期：2014.11

  An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J. 2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases. Virtual screening identified fragments that could be fused into the core scaffold, exploiting additional binding interactions and thus improving potency. These efforts resulted in a hybrid compound with target potency increased by a 1000-fold, while maintaining selectivity against selected protein kinases and an improved level of solubility and protein binding. Despite these significant improvements no significant antibacterial activity was yet observed within this class. (C) 2014 Elsevier Ltd. All rights reserved.